Company Overview and News

 
Cogeco Communications inc. participera à la 17th Annual Eastern Institutional Investor Conference de la CIBC

2018-09-21 globenewswire
MONTRÉAL, 21 sept. 2018 (GLOBE NEWSWIRE) -- Cogeco Communications inc. (TSX : CCA), annonce aujourd’hui qu’elle participera à la 17th Annual Eastern Institutional Investor Conference de la CIBC, qui aura lieu à Montréal, Québec. M. Louis Audet, le président exécutif du conseil d’administration de Cogeco Communications inc., participera à une discussion interactive dans le cadre de cette conférence le mercredi 26 septembre 2018 à 10 h 00 (heure avancée de l’Est).
CGEAF

 
Cogeco Communications Inc. to Participate in CIBC’s 17th Annual Eastern Institutional Investor Conference

2018-09-21 globenewswire
MONTREAL, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Cogeco Communications Inc. (TSX: CCA) announced today that it will be participating in CIBC’s 17th Annual Eastern Institutional Investor Conference to be held in Montréal, Québec. As part of this conference Mr. Louis Audet, Cogeco Communications Inc.’s Executive Chairman of the Board, will participate in an interactive discussion on Wednesday, September 26, 2018 at 10 a.
CCA CGEAF

 
Cogeco inc. et Cogeco Communications inc. annoncent la date de divulgation de leurs résultats financiers du quatrième trimestre de l’exercice 2018 et de la conférence téléphonique

2018-09-18 globenewswire
MONTRÉAL, 18 sept. 2018 (GLOBE NEWSWIRE) -- Cogeco inc. (TSX : CGO) et Cogeco Communications inc. (TSX : CCA) planifient de divulguer leurs résultats financiers du quatrième trimestre de l’exercice 2018, terminé le 31 août 2018, le mercredi 31 octobre 2018, après la fermeture des marchés boursiers.
CGEAF

 
Cogeco Inc. and Cogeco Communications Inc. Schedule the Release of their Financial Results for the Fourth Quarter of Fiscal 2018 and Related Conference Call

2018-09-18 globenewswire
MONTREAL, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Cogeco Inc. (TSX: CGO) and Cogeco Communications Inc. (TSX: CCA) plan to release their financial results for the fourth quarter ended August 31, 2018 on Wednesday, October 31, 2018, after market closing.
CGO CCA CGECF CGEAF

 
Cogeco Communications Inc. participera à la BMO Capital Markets’ 19th Annual Media & Telecom Conference

2018-09-05 globenewswire
MONTRÉAL, 05 sept. 2018 (GLOBE NEWSWIRE) -- Cogeco Communications inc. (TSX : CCA) annonce aujourd’hui qu’elle participera à la BMO Capital Markets’ 19th Annual Media & Telecom Conference, qui aura lieu le 12 septembre 2018, à Toronto, Ontario. M. Louis Audet, président exécutif du conseil d’administration de Cogeco Communications inc., participera à une discussion interactive à 11 h 15 (HAE).
CGEAF

 
Cogeco Communications Inc. to Participate in BMO Capital Markets’ 19th Annual Media & Telecom Conference

2018-09-05 globenewswire
MONTRÉAL, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Cogeco Communications Inc. (TSX: CCA) announced today that it will be participating in BMO Capital Markets’ 19th Annual Media & Telecom Conference to be held in Toronto, Ontario, September 12, 2018. Louis Audet, Executive Chair of the Board of Directors of Cogeco Communications Inc., will participate in an interactive discussion at 11:15 a.m. (EDT).
CCA CGEAF

 
Cogeco Announces Renewal of Its Normal Course Issuer Bid

2018-07-30 globenewswire
MONTREAL, July 30, 2018 (GLOBE NEWSWIRE) -- Cogeco Inc. (TSX: CGO) (the "Corporation" or "Cogeco") announces that the Toronto Stock Exchange (the "TSX") has accepted its notice of intention for a normal course issuer bid in respect of its Subordinate Voting Shares (the "Subordinate Shares"). Purchases pursuant to the notice will not commence prior to August 2, 2018, the date following the date upon which the Corporation’s current normal course issuer bid is set to expire, and will not continue beyond August 1, 2019.
CGO CCA CGECF CGEAF

 
Cogeco annonce le renouvellement de son offre publique de rachat dans le cours normal des activités

2018-07-30 globenewswire
MONTRÉAL, 30 juill. 2018 (GLOBE NEWSWIRE) -- Cogeco inc. (TSX : CGO) (la « Société » ou « Cogeco ») annonce que la Bourse de Toronto (la « TSX ») a accepté son avis d’intention de procéder à une offre publique de rachat dans le cours normal des activités relativement à ses actions subalternes à droit de vote (les « actions subalternes »). Les rachats d’actions subalternes aux termes de cet avis pourront commencer le 2 août 2018, et ne se poursuivront pas au-delà du 1er août 2019.
CGEAF

 
Atlantic Broadband Deploys SeaChange Solutions for New IP VOD Service

2018-07-30 globenewswire
ACTON, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Video solutions pioneer SeaChange International Inc. (NASDAQ: SEAC) today announced a significant deployment of its new cFlow™ video solutions portfolio with Atlantic Broadband, the country’s ninth largest cable operator. The new Internet Protocol (IP) Video On Demand (VOD) service is now available in Atlantic Broadband’s Connecticut, New Hampshire and Maine service areas, with deployments planned for its other markets by year’s end.
VCM SEAC CCA CGEAF

 
Cogeco Communications inc. annonce une succession à la direction de Cogeco Peer 1

2018-07-30 globenewswire
Susan Bowen nommée présidente de la filiale des services de technologies de l’information et des communications aux entreprises de la société
CCA CGEAF HPE

 
 Cogeco Communications Inc. Announces a Leadership Succession at Cogeco Peer 1

2018-07-30 globenewswire
MONTREAL, July 30, 2018 (GLOBE NEWSWIRE) -- Cogeco Communications Inc. (TSX:CCA) (“Cogeco Communications”) is pleased to announce the appointment of Susan Bowen to the position of President of Cogeco Peer 1, effective September 1, 2018. Ms. Bowen is currently Vice President and General Manager, Europe, Middle East & Africa (EMEA) at Cogeco Peer 1. This change in leadership follows the appointment of Philippe Jetté, current President of Cogeco Peer 1, to the position of President and Chief Executive Officer of Cogeco Inc.
CCA CGECF CGEAF HPE

 
Is Cogeco Communications' Decelerating Internet Customers Growth A Concern?

2018-07-19 seekingalpha
Entry into wireless service appears to be a good strategy to defend its broadband Internet market share as it allows Cogeco to bundle its services.
RCIAF RCI SJR.B CCA SJR SJRWF CGEAF TU QBCRF SJR.A

 
Cogeco Communications, Inc. (CGEAF) CEO Louis Audet on Q3 2018 Results - Earnings Call Transcript

2018-07-12 seekingalpha
Cogeco Communications, Inc. (OTCPK:CGEAF) Q3 2018 Results Earnings Conference Call July 12, 2018 11:00 AM ET
CGEAF

 
Cogeco Communications Inc 2018 Q3 - Results - Earnings Call Slides

2018-07-12 seekingalpha
The following slide deck was published by Cogeco Communications Inc in conjunction with their 2018 Q3 earnings call.
CGEAF

 
Cogeco Communications Releases Its Results for the Third Quarter of Fiscal 2018

2018-07-11 globenewswire
MONTRÉAL, July 11, 2018 (GLOBE NEWSWIRE) -- Today, Cogeco Communications Inc. (TSX:CCA) (“Cogeco Communications” or the “Corporation”) announced its financial results for the third quarter ended May 31, 2018, in accordance with International Financial Reporting Standards (“IFRS”).
CCA CGEAF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 19239C106